IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 CHF | +9.07% |
|
-3.55% | -10.12% |
| Apr. 26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
| Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
ETFs positioned on Idorsia Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 152 M€ | -3.56% | - | |
| 0.00% | 26 M€ | -4.26% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -3.48% | - |
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-05-21
- Q1 2024 Earnings Release - Q4 2023
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.9
CHF
Average target price
1.724
CHF
Spread / Average Target
-9.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.12% | 371M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IDIA Stock
- Funds and ETFs Idorsia Ltd
